PharmaTher Announces FDA Approval of Ketamine (KETARx™)

PharmaTher Announces FDA Approval of Ketamine (KETARx™)

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and…

FDA Okays Ketamine-Based Med for Post-Surgical Pain

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical pain. “This historic FDA approval…is a testament to years of dedicated development,” Fabio Chianelli, chairman and CEO of PharmaTher, said in a release. “We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for […] The post FDA Okays Ketamine-Based Med for Post-Surgical Pain first appeared o…

Major FDA Breakthrough: PharmaTher's Ketamine Treatment Targets $3.4B Market Opportunity

Groundbreaking FDA approval positions PharmaTher's KETARx in $3.4B ketamine market. New treatment targets surgical pain, mental health, and neurological disorders. Learn more.